Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary

M. M. Chren and C. S. Landefeld
Department of Dermatology, Cleveland (Ohio) Veterans Affairs Medical Center, University Hospitals of Cleveland 44106.

OBJECTIVE--It is controversial whether physicians' interactions with drug companies affect their behavior. To test the null hypothesis, that such interactions are not associated with physician behavior, we studied one behavior: requesting that a drug be added to a hospital formulary. DESIGN--Nested case-control study. SETTING--University hospital. PARTICIPANTS--Full-time attending physicians. Case physicians were all 40 physicians who requested a formulary addition from January 1989 through October 1990. Control physicians were 80 randomly selected physicians who had not made requests. MAIN EXPOSURE MEASURE--Physician interactions with drug companies, as determined by survey of physicians (response rate, 88% [105/120]). RESULTS--Physicians who had requested that drugs be added to the formulary interacted with drug companies more often than other physicians; for example, they were more likely to have accepted money from companies to attend or speak at educational symposia or to perform research (odds ratio [OR], 5.1; 95% confidence interval [CI], 2.0 to 13.2). Furthermore, physicians were more likely than other physicians to have requested that drugs manufactured by specific companies be added to the formulary if they had met with pharmaceutical representatives from those companies (OR, 13.2; 95% CI, 4.8 to 36.3) or had accepted money from those companies (OR, 19.2; 95% CI, 2.3 to 156.9). These associations were consistent in multivariable analyses controlling for potentially confounding factors. Moreover, physicians were more likely to have requested formulary additions made by the companies whose pharmaceutical representatives they had met (OR, 4.9; 95% CI, 3.2 to 7.4) or from whom they had accepted money (OR, 1.7; 95% CI, 1.0 to 2.7) than they were to have requested drugs made by other companies. CONCLUSION--Requests by physicians that drugs be added to a hospital formulary were strongly and specifically associated with the physicians' interactions with the companies manufacturing the drugs.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Has the hunt for conflicts of interest gone too far? No
Lee
BMJ 2008;336:477-477.
FULL TEXT  

Is continuing medical education a drug-promotion tool?: YES
Steinman and Baron
cfp 2007;53:1650-1653.
FULL TEXT  

La formation medicale continue est-elle un outil de promotion pharmaceutique?: OUI
Steinman and Baron
cfp 2007;53:1654-1657.
FULL TEXT  

The High Cost of Free Lunch
Wall and Brown
Obstet Gynecol 2007;110:169-173.
ABSTRACT | FULL TEXT  

Physicians' intent to comply with the American Medical Association's guidelines on gifts from the pharmaceutical industry
Pinto et al.
J. Med. Ethics 2007;33:313-319.
ABSTRACT | FULL TEXT  

Pharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and Minnesota
Ross et al.
JAMA 2007;297:1216-1223.
ABSTRACT | FULL TEXT  

Interactions Between Physicians and Industry: A Guide for Clinicians
Jibson
Focus 2007;5:398-406.
ABSTRACT | FULL TEXT  

Bibliography for Ethics, Professionalism, and End of Life Care
Focus 2007;5:417-419.
FULL TEXT  

Industry gifts to healthcare providers: are the concerns serious?
Day
Am J Crit Care 2006;15:510-513.
FULL TEXT  

How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug Preferences
Andersen et al.
JAMA 2006;295:2759-2764.
ABSTRACT | FULL TEXT  

Conflicts of interest: how money clouds objectivity.
Smith
JRSM 2006;99:292-297.
FULL TEXT  

Medical Education and the Pharmaceutical Industry: Managing an Uneasy Alliance
Jibson
Acad. Psychiatry 2006;30:36-39.
FULL TEXT  

Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers
Brennan et al.
JAMA 2006;295:429-433.
ABSTRACT | FULL TEXT  

The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior
Huang et al.
Acad. Psychiatry 2005;29:500-501.
FULL TEXT  

Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey
Sierles et al.
JAMA 2005;294:1034-1042.
ABSTRACT | FULL TEXT  

Psychiatric Training Program Engagement With the Pharmaceutical Industry: An Educational Issue, Not Strictly an Ethical One
Mohl
Acad. Psychiatry 2005;29:215-221.
ABSTRACT | FULL TEXT  

The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem
Brodkey
Acad. Psychiatry 2005;29:222-229.
ABSTRACT | FULL TEXT  

The role of the pharmaceutical industry in neurologic education
Gelb
Neurology 2005;64:E7-E10.
FULL TEXT  

Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry -- Self-Regulation in the Shadow of Federal Prosecution
Studdert et al.
NEJM 2004;351:1891-1900.
FULL TEXT  

Reimbursement Incentives to Physicians
Capozzi and Delsignore
JBJS 2004;86:876-877.
FULL TEXT  

Factors that Influence Prescribing Decisions
Schumock et al.
The Annals of Pharmacotherapy 2004;38:557-562.
ABSTRACT | FULL TEXT  

Primer on Medical Professionalism
Diaz and Stamp
J. Am. Podiatr. Med. Assoc. 2004;94:206-209.
ABSTRACT | FULL TEXT  

Authors' Financial Relationships With the Food and Beverage Industry and Their Published Positions on the Fat Substitute Olestra
Levine et al.
Am. J. Public Health 2003;93:664-669.
ABSTRACT | FULL TEXT  

Changing Use of Antibiotics in Community-Based Outpatient Practice, 1991-1999
Steinman et al.
ANN INTERN MED 2003;138:525-533.
ABSTRACT | FULL TEXT  

Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and {beta}-Blockers?
Saseen et al.
J Am Board Fam Med 2003;16:156-164.
FULL TEXT  

Predictors of Broad-Spectrum Antibiotic Prescribing for Acute Respiratory Tract Infections in Adult Primary Care
Steinman et al.
JAMA 2003;289:719-725.
ABSTRACT | FULL TEXT  

Medical Education and Corporate Sponsorship
Capozzi et al.
JBJS 2003;85:168-170.
ABSTRACT | FULL TEXT  

Financial Conflicts of Interest in Human Subjects Research: The Problem of Institutional Conflicts
Barnes and Florencio
J Law Med Ethics 2002;30:390-402.
 

Physician-Industry Relations. Part 1: Individual Physicians
Coyle and for the Ethics and Human Rights Committee, America
ANN INTERN MED 2002;136:396-402.
ABSTRACT | FULL TEXT  

Long-Term Effects of Restricting Residents' Contacts with Drug Representatives
Comerci
AAP Grand Rounds 2002;7:32-32.
FULL TEXT  

From Clinical Trial to Prescription
Carpenter
Arch Gen Psychiatry 2002;59:282-285.
ABSTRACT | FULL TEXT  

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
Choudhry et al.
JAMA 2002;287:612-617.
ABSTRACT | FULL TEXT  

Effect of Restricting Contact Between Pharmaceutical Company Representatives and Internal Medicine Residents on Posttraining Attitudes and Behavior
McCormick et al.
JAMA 2001;286:1994-1999.
ABSTRACT | FULL TEXT  

The Problem of Medical Misadventures: A Review of E. Haavi Morreim's Holding Health Care Accountable
Furrow
J Law Med Ethics 2001;29:381-393.
 

Conflict of Interest and the Public Trust
DeAngelis
JAMA 2000;284:2237-2238.
FULL TEXT  

Medical Professionalism -- Focusing on the Real Issues
Rothman
NEJM 2000;342:1284-1286.
FULL TEXT  

Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana
JAMA 2000;283:373-380.
ABSTRACT | FULL TEXT  

Conflict of Interest and Cost-effectiveness Analysis
Krimsky
JAMA 1999;282:1474-1475.
FULL TEXT  

Accepting commercial sponsorship
Bero
BMJ 1999;319:653-654.
FULL TEXT  

Beyond conflict of interest
Smith
BMJ 1998;317:291-292.
FULL TEXT  

Conflict of Interest in the Debate over Calcium-Channel Antagonists
Meltzer et al.
NEJM 1998;338:1696-1698.
FULL TEXT  

What Have We Learned From the Calcium Channel Blocker Controversy?
Califf and Kramer
Circulation 1998;97:1529-1531.
FULL TEXT  

Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox et al.
NEJM 1998;338:101-106.
ABSTRACT | FULL TEXT  

GPs' prescribing behaviour may be affected by drug promotion
Gill et al.
BMJ 1996;313:367a-367.
FULL TEXT  

Buying Editorials
Brennan
NEJM 1994;331:673-675.
FULL TEXT